Kennedy receives $570,600 NCI award for cancer research

Kennedy, Eileen-h.portrait

September 22, 2011

Print
Share    
Writer:
Sheila Roberson

Sheila Roberson

Public Relations Coordinator

Recent and archived articles by Sheila Roberson


College of Pharmacy
Work: 706-542-5303
Email:

Contact:
Eileen Kennedy

Eileen Kennedy

Assistant Professor

Pharmaceutical and Biomedical Sciences
College of Pharmacy
Work: 706/542-6497
Email:
,

Photography

  • magnify Kennedy, Eileen-h.portrait

    Eileen Kennedy

Scroll Left 1 Scroll Right

Related Sites

Athens, Ga. - Eileen Kennedy, assistant professor of pharmaceutical and biomedical sciences in the University of Georgia College of Pharmacy, received a National Cancer Institute Transition Career Development Award from the National Institutes of Health for more than $570,600 over the next three years. Her project will look at specific mechanisms related to breast cancer.

The award is designed to help academic professionals working in cancer research transition from the mentored stage to the independent stage of their careers. Investigators must be within the first two years of their first independent cancer research positions. The award gives them protected time through salary and research support for three years, in order to help them initiate and develop their independently supported cancer research programs.

Additionally, the award helps assure that a diverse pool of highly trained scientists from under-represented populations are available in adequate numbers and in appropriate research areas to address the nation's biomedical, behavioral and clinical research needs.

Kennedy joined the College of Pharmacy in 2010. Her cancer research focuses on studying spatiotemporal regulation of kinases as it relates to cancer. Kinases are enzymes that help regulate signaling processes. They have been implicated in development and disease issues, including cancer.

A-kinase anchoring proteins act as a regulatory mechanism for some kinases, promoting subcellular localization near specific targets. Although AKAP mutations have been linked to cancer, it isn't clear how these subcellular mislocalizations lead to disease.

Kennedy's goal is to develop synthetic agents to use as investigative tools. She hopes to disrupt protein-protein interactions mediated by AKAPs in order to uncover specific cell signaling events in breast cancer.

Filed under: Medical Science, Cancer

News Service

Director
Cynthia Hoke

706 / 542-8083
Public Relations Coordinator
Stephanie Schupska

706 / 542-6927
Public Relations Coordinator
Sara Freeland

706 / 542-8077
Science Writer
April Sorrow

706 / 542-7991

Broadcast, Video and Photography

Director
Steve Bell

706 / 542-8089
Broadcast Coordinator
Pete Konenkamp

706 / 542-8080
Photography
Rick O‘Quinn

706 / 542-8085